Percheron Therapeutics (AU:PER) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Percheron Therapeutics Limited (ASX: PER) has requested a trading halt on its securities as it prepares to release initial top line data from a phase IIb clinical trial of its drug avicursen for Duchenne muscular dystrophy. The halt will remain in effect until the announcement is made or normal trading resumes on December 18, 2024. Investors are keenly awaiting these results, which could have significant implications for the company’s stock performance.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
